Disclosure of transfers of value in 2024
As an affiliate of Medicines for Europe, and based on its Code of Conduct, Medicines UK asks that member companies record and publish their transfers of value (in kind or actual) for the previous calendar year (2024) to healthcare professionals, healthcare organisations and patient organisations. Members can publish their return on their own websites, on another publicly accessible website (notably on Disclosure UK) or on Medicines UK's website.
Annual transfer of values 2024
The following companies have requested that Medicines UK publish their annual transfers of value for 2024.
.
| Company | Number of healthcare or patient organisations or healthcare professionals receiving a transfer of value | Category of transfer of value (£) | Total value (£) |
| Aspire Pharma | 16 healthcare professionals | Consultancy costs and fees for services (ranging from 200 to 58,000) | 69,666.25 |
| 9 healthcare organisations | Therapy review services and event sponsorship (ranging from 250 to 194,000) | 314,395.78 | |
| 2 patient organisations
| Donations and event sponsorship (ranging from 2,500 to 15,000) | 17,500.00 | |
| Hikma (UK) | Nil return | ||
| Reig Jofre UK | Nil return | ||
| Dexcel Pharma Ltd | Nil return | ||
| MSN Labs | Nil return | ||
| Panpharma UK Ltd | Nil return |
For queries, please contact robert.russellpavier@medicinesuk.com.
Latest industry news
Partnership will revive inactive licences to solve critical medicines shortages
By Jeremy Durrant